Comparative efficacies of different immunotherapy regimens in recurrent implantation failure: A systematic review and network meta-analysis
Caiyun Wang,Defeng Guan,Rui Li,Zhitong Bing,Yongxiu Yang,Kehu Yang
DOI: https://doi.org/10.1016/j.jri.2021.103429
IF: 3.993
2021-11-01
Journal of Reproductive Immunology
Abstract:For patients with recurrent implantation failure (RIF), immune system imbalances have become the focus of research. The effects of different classes of immunotherapies on improving pregnancy outcomes have not been fully established. This network meta-analysis was performed to assess the impact of popular immunotherapies in women with RIF. We systematically searched the Cochrane Central Register of Controlled Trials, PubMed, Embase, and Web of Science databases as well as clinical trial registration websites. Randomized controlled trials comparing immunotherapeutic outcomes were included. We performed the random-effects network meta-analysis to compare efficacy measures. A total of 21 trials involving 2277 participants and 8 immunotherapies were eligible for this study. Patients that had been administered with PBMCs, G-CSF, PRP, and sirolimus exhibited higher CPR than those administered with the placebo (2.63, 1.71 to 4.06; 2.03, 1.35 to 3.05; 1.98, 1.02 to 3.84; 2.55, 1.36 to 4.79; and 3.95, 1.33 to 11.72, respectively). For IR, only PBMCs and G-CSF were significantly more effective than the placebo (2.92, 1.39 to 6.12; 2.66, 1.16 to 6.06, respectively). In terms of LBR, PBMCs (2.96, 1.67 to 5.27) and sirolimus (3.55, 1.18 to 10.64) were effective. However, r-hLIF (0.25, 0.10 to 0.62) had a reduced risk of LBR. No therapeutic regimen was found to have significantly decreased MR, but PBMCs exhibited the lowest rank among all interventions (0.28, 0.06 to 1.44). To improve clinical pregnancy while reducing miscarriage outcomes, PBMCs might be a beneficent therapeutic option for RIF in the future
immunology,reproductive biology